Programmed death‐1 (PD‐1) and programmed death‐1 ligand‐1 (PDL‐1), cancer immunotherapy, principally PD‐1/PD‐L1 pathway blockade, shows high feasibility.9 This evidence concerns the gene CD274 and cancer.